Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

PledPharma publ AB Announces Results from MANAMI-Study in Patients with Acute Myocardial Infarction


Monday, 14 Oct 2013 02:00am EDT 

PledPharma publ AB announced results from the MANAMI-study in patients with acute myocardial infarction. In a small clinical (feasibility) study mangafodipir was given as an adjunct to balloon dilatation (PCI) in patients with acute myocardial infarction. Ten patients received intravenous (iv) infusion of mangafodipir and 10 patients received saline (placebo). All patients experienced their first episode of serious infarction (STEMI). They were transferred to the PCI laboratory for assessment of coronary artery occlusion and reduction of blood flow to the ischemic region. Mangafodipir or saline was given iv over 2-5 minutes (min) just prior to PCI and reopening of the occluded artery. Patients tolerated iv infusion of mangafodipir well without any side-effects. Magnetic resonance imaging (MRI) at ambulant control showed a tendency of smaller infarcts (26% vs. 32% for the placebo group) and improved cardiac pump function (48% vs. 42% for the placebo group) in those who received mangafodipir. This was in spite of an odd distribution between groups in disfavor of mangafodipir. Thus the mangafodipir group had a significant longer period of chest pain (206 min vs. 144 min for the placebo group) prior to PCI. 

Company Quote

21.6
-0.4 -1.82%
22 Sep 2014